BC
FATE icon

Boxer Capital’s Fate Therapeutics FATE Stock Holding History

Boxer Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,960,910
Closed -$17.4M – 16
2024
Q3 		$17.4M Sell
4,960,910
-3,255,000
-40% -$12.7M 0.85% 33
2024
Q2 		$26.9M Hold
8,215,910
– – 1.42% 20
2024
Q1 		$60.3M Buy
8,215,910
+7,715,910
+1,543% +$47.8M 2.98% 13
2023
Q4 		$1.87M Hold
500,000
– – 0.09% 42
2023
Q3 		$1.06M Hold
500,000
– – 0.06% 63
2023
Q2 		$2.38M Hold
500,000
– – 0.11% 64
2023
Q1 		$2.85M Sell
500,000
-750,000
-60% -$4.53M 0.14% 60
2022
Q4 		$12.6M Buy
1,250,000
+900,000
+257% +$16.9M 0.66% 40
2022
Q3 		$7.84M Sell
350,000
-150,000
-30% -$4.33M 0.44% 43
2022
Q2 		$12.4M Hold
500,000
– – 0.78% 41
2022
Q1 		$19.4M Hold
500,000
– – 1% 32
2021
Q4 		$29.3M Buy
+500,000
New +$28.3M 1.14% 23

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Boxer Capital's FATE Position: Q4 2024 in Review

Boxer Capital sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 4,960,910 shares — an estimated $17.4M sold.

Boxer Capital first reported a position in FATE in Q4 2021 and held it in 12 quarters. The position peaked at $60.3M in Q1 2024. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Boxer Capital reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 4,960,910 Fate Therapeutics shares in Q4 2024, an estimated $17.4M.
  • Boxer Capital first reported a position in Fate Therapeutics in Q4 2021 and held it in 12 quarters.
  • Boxer Capital's Fate Therapeutics position peaked at $60.3M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.